Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Pharmacotherapy for obesity
- Phentermine
- Phentermine: methods
- Phentermine: results
- Weight loss with phentermine
- Phentermine: conclusions
- Topiramate
- Topiramate: introduction
- Topiramate: dose escalation
- Topiramate: study randomization protocol
- Topiramate: results
- Topiramate: complications
- Phentermine plus topiramate
- Phentermine + topiramate: randomization protocol
- Phentermine + topiramate: results
- Phentermine + topiramate: side effects
- First Australian phentermine + topiramate trial (1)
- First Australian phentermine + topiramate trial (2)
- Phentermine + topiramate: results (Australia)
- Phentermine + topiramate: conclusion (Australia)
- Orlistat
- Orlistat: introduction
- Orlistat: methods
- Orlistat: results (1)
- Orlistat: complications
- Orlistat: results (2)
- Liraglutide
- Liraglutide: randomization protocol
- Liraglutide: results
- Liraglutide: side effects
- Lorcaserin
- Lorcaserin: aim
- Lorcaserin: patients
- Lorcaserin: intervention
- Lorcaserin: main outcome measures
- Lorcaserin: results (1)
- Lorcaserin: results (2)
- Lorcaserin: side effects
- Lorcaserin: conclusion
- Naltrexone plus bupropion
- Naltrexone plus bupropion: introduction
- Naltrexone plus bupropion: methods (1)
- Naltrexone plus bupropion: methods (2)
- Naltrexone plus bupropion: results
- Naltrexone plus bupropion: side effects
- Medications under investigation
- Semaglutide
- Semaglutide: methods
- Semaglutide: results (1)
- Semaglutide: results (2)
- Pramlintide (amylin)
- Pramlintide: aim
- Pramlintide: methods
- Pramlintide: results
- Pramlintide: side effects
- Pramlintide: conclusions
- Metreleptin (leptin)
- Metreleptin: aim
- Metreleptin: methods
- Metreleptin: results (1)
- Metreleptin: results (2)
- Pramlintide plus metreleptin
- Pramlintide plus metreleptin: aim
- Pramlintide plus metreleptin: methods
- Pramlintide plus metreleptin: results
- Beloranib
- Beloranib: aim
- Beloranib: methods
- Beloranib: results
- Beloranib: side effects
- Beloranib: Post Script
- Combination of hormones
- Combination of hormones: aim
- Combination of hormones: methods
- Combination of hormones: results (1)
- Combination of hormones: results (2)
- Major points about weight loss medications
Topics Covered
- Clinical studies involving pharmacological drugs for the treatment of obesity
- Phentermine
- Topiramate
- Phentermine plus topiramate
- Orlistat
- Liraglutide
- Lorcaserin
- Naltrexone plus bupropion
- Semaglutide
- Pramlintide
- Metreleptin
- Pramlintide plus metreleptin
- Beloranib
- Combination of hormones
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Proietto, J. (2018, December 31). Pharmacotherapy for obesity 2 - pharmacological agents in current use & under development [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/QXEB9338.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Joe Proietto, Speakers' Bureau: Nova Pharmaceuticals; Consulting Fees (e.g., advisory boards), Honoraria: Novo Nordisk
Pharmacotherapy for obesity 2 - pharmacological agents in current use & under development
Published on December 31, 2018
46 min
Other Talks in the Series: Obesity: Science, Medicine and Society
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome back to the second part of this talk where I'll be reviewing
the medications that are approved somewhere in the world for managing obesity
or, are under active development at the moment.
0:18
So, what pharmacotherapy do we have?
The drugs listed in the next slide,
are those that have been approved for use in
one or another country around the world and there are seven of them at the moment:
phentermine, topiramate, a combination of phentermine and topiramate,
orlistat, liraglutide, lorcaserin, and naltrexone plus bupropion.
We should say when looking at this slide that all
except orlistat work in the brain to suppress hunger.
0:60
The next slide is the first of the studies that we'll discuss that was
published in 1968 where they investigated phentermine.
1:12
They studied 108 women, aged between 21 and 60 years who were obese,
and they divided the group into three groups of 36 subjects each,
that were all placed on a 1000 calorie diet,
and then, group one was placed on placebo-
they were given four weekly supplies.
Group two was given phentermine 30 milligrams, and group three,
was given phentermine for one month, alternating
with placebo the next month and then, back again to phentermine.
Hide